HC Wainwright Has Positive Outlook for RVPH FY2025 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Equities researchers at HC Wainwright upped their FY2025 earnings estimates for Reviva Pharmaceuticals in a research report issued on Tuesday, December 23rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.32) for the year, up from their prior estimate of ($0.42). HC Wainwright currently has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q4 2025 earnings at ($0.06) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.25) EPS.

RVPH has been the topic of several other reports. D. Boral Capital reaffirmed a “buy” rating and set a $2.00 price objective on shares of Reviva Pharmaceuticals in a research report on Tuesday. Wall Street Zen raised shares of Reviva Pharmaceuticals to a “sell” rating in a report on Saturday, October 4th. Chardan Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Benchmark lowered their price target on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Reviva Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $3.86.

Reviva Pharmaceuticals Trading Down 11.6%

RVPH stock opened at $0.28 on Thursday. The stock’s 50 day simple moving average is $0.56 and its 200 day simple moving average is $0.52. Reviva Pharmaceuticals has a 12-month low of $0.25 and a 12-month high of $2.17. The stock has a market capitalization of $32.68 million, a PE ratio of -0.62 and a beta of -0.02.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.05.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd purchased a new position in Reviva Pharmaceuticals during the second quarter valued at $31,000. Lido Advisors LLC bought a new position in shares of Reviva Pharmaceuticals during the 3rd quarter valued at about $37,000. NewEdge Advisors LLC purchased a new position in shares of Reviva Pharmaceuticals during the first quarter valued at about $58,000. Geode Capital Management LLC increased its holdings in shares of Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares during the last quarter. Finally, Persistent Asset Partners Ltd lifted its position in shares of Reviva Pharmaceuticals by 300.0% in the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after buying an additional 480,864 shares in the last quarter. 63.18% of the stock is owned by institutional investors.

Key Reviva Pharmaceuticals News

Here are the key news stories impacting Reviva Pharmaceuticals this week:

• Positive Sentiment: Analyst bullishness — HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target, implying large upside versus the current price; this bullish call likely fuels speculative interest. Read More.
• Positive Sentiment: Additional buy reiteration — D. Boral Capital maintained a “buy” rating with a $2.00 target, another institutional endorsement that can support upside momentum. Read More.
• Positive Sentiment: Heavy call option buying — traders purchased large volumes of call options (roughly 25,745 calls, ~295% above typical volume), which indicates speculative bullish positioning that can amplify intraday price moves. Read More.
• Neutral Sentiment: Short-interest data flagged as zero/incomplete — reported short interest shows 0 shares (data appears unreliable/NaN change), so it provides no clear signal on short-seller positioning. No meaningful short-squeeze implication from this report.
• Negative Sentiment: Regulatory setback — the FDA recommended a second Phase 3 trial for brilaroxazine in schizophrenia after a pre-NDA meeting, meaning more time, data and cost before potential approval; this is the primary driver of the stock decline. Read More.
• Negative Sentiment: Funding and dilution risk — analysts (Roth) warn Reviva may need an additional $60M–$75M to complete the schizophrenia study, raising dilution and financing concerns that weigh on valuation. Read More.
• Negative Sentiment: Price-target cuts and market reaction — Roth lowered its price target to $1.50 (from $3), and coverage/ headlines note a sharp intraday plunge after the FDA news, reinforcing negative sentiment and selling pressure. Read More. Read More.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.